======= IRF8 ======= == Gene Information == * **Official Symbol**: IRF8 * **Official Name**: interferon regulatory factor 8 * **Aliases and Previous Symbols**: N/A * **Entrez ID**: [[https://www.ncbi.nlm.nih.gov/gene/?term=3394|3394]] * **UniProt**: [[https://www.uniprot.org/uniprot/Q02556|Q02556]] * **Interactions**: [[https://thebiogrid.org/search.php?search=IRF8&organism=9606|BioGRID]] * **PubMed articles**: [[https://www.ncbi.nlm.nih.gov/pubmed/?term=gene%20IRF8|Open PubMed]] * **OMIM**: [[https://omim.org/entry/601565|Open OMIM]] == Function Summary == * **Entrez Summary**: Interferon consensus sequence-binding protein (ICSBP) is a transcription factor of the interferon (IFN) regulatory factor (IRF) family. Proteins of this family are composed of a conserved DNA-binding domain in the N-terminal region and a divergent C-terminal region that serves as the regulatory domain. The IRF family proteins bind to the IFN-stimulated response element (ISRE) and regulate expression of genes stimulated by type I IFNs, namely IFN-alpha and IFN-beta. IRF family proteins also control expression of IFN-alpha and IFN-beta-regulated genes that are induced by viral infection. [provided by RefSeq, Jul 2008]. * **UniProt Summary**: Plays a role as a transcriptional activator or repressor (PubMed:25122610). Specifically binds to the upstream regulatory region of type I IFN and IFN-inducible MHC class I genes (the interferon consensus sequence (ICS)). Plays a negative regulatory role in cells of the immune system. Involved in CD8(+) dendritic cell differentiation by forming a complex with the BATF-JUNB heterodimer in immune cells, leading to recognition of AICE sequence (5'-TGAnTCA/GAAA-3'), an immune-specific regulatory element, followed by cooperative binding of BATF and IRF8 and activation of genes (By similarity). {ECO:0000250|UniProtKB:P23611, ECO:0000269|PubMed:25122610}. |IRF-3| |IRF| |defense response to protozoan| |response to protozoan| |positive regulation of interleukin-12 production| |regulation of interleukin-12 production| |positive regulation of interferon-gamma production| |type I interferon signaling pathway| |cellular response to type I interferon| |response to type I interferon| |interferon-gamma-mediated signaling pathway| |regulation of interferon-gamma production| |cellular response to interferon-gamma| |response to interferon-gamma| |cellular response to lipopolysaccharide| |cellular response to molecule of bacterial origin| |cellular response to biotic stimulus| |myeloid cell differentiation| |DNA-binding transcription repressor activity, RNA polymerase II-specific| |autophagy| |process utilizing autophagic mechanism| |response to lipopolysaccharide| |response to molecule of bacterial origin| |phagocytosis| |defense response to bacterium| |positive regulation of cytokine production| |RNA polymerase II proximal promoter sequence-specific DNA binding| |cellular response to lipid| |hemopoiesis| |hematopoietic or lymphoid organ development| |immune system development| |cytokine-mediated signaling pathway| |response to bacterium| |regulation of cytokine production| |innate immune response| |response to lipid| |negative regulation of transcription by RNA polymerase II| |defense response to other organism| |cellular response to cytokine stimulus| |cellular response to oxygen-containing compound| |response to cytokine| |negative regulation of transcription, DNA-templated| |positive regulation of transcription by RNA polymerase II| |negative regulation of nucleic acid-templated transcription| |negative regulation of RNA biosynthetic process| |response to other organism| |response to external biotic stimulus| |response to biotic stimulus| |negative regulation of RNA metabolic process| |defense response| |negative regulation of cellular macromolecule biosynthetic process| |negative regulation of nucleobase-containing compound metabolic process| |negative regulation of macromolecule biosynthetic process| |negative regulation of cellular biosynthetic process| |positive regulation of transcription, DNA-templated| |negative regulation of biosynthetic process| |response to oxygen-containing compound| |DNA-binding transcription factor activity, RNA polymerase II-specific| |positive regulation of nucleic acid-templated transcription| |positive regulation of RNA biosynthetic process| |negative regulation of gene expression| |positive regulation of RNA metabolic process| |positive regulation of multicellular organismal process| |cellular catabolic process| |immune response| |positive regulation of nucleobase-containing compound metabolic process| |positive regulation of macromolecule biosynthetic process| |vesicle-mediated transport| |positive regulation of cellular biosynthetic process| |positive regulation of gene expression| |positive regulation of biosynthetic process| \\ === CRISPR Data === ^Screen^Score^ |[[:results:exp516|Pyrazinamide 100μM R08 exp516]]|-2.17| No correlation found to any other genes in chemogenomics. Global Fraction of Cell Lines Where Essential: 2/739 ^Tissue^Fraction Of Cell Lines Where Essential^ |1290807.0|0/1| |909776.0|0/1| |bile duct|0/28| |blood|2/28| |bone|0/26| |breast|0/33| |central nervous system|0/56| |cervix|0/4| |colorectal|0/17| |esophagus|0/13| |fibroblast|0/1| |gastric|0/16| |kidney|0/21| |liver|0/20| |lung|0/75| |lymphocyte|0/16| |ovary|0/26| |pancreas|0/24| |peripheral nervous system|0/16| |plasma cell|0/15| |prostate|0/1| |skin|0/24| |soft tissue|0/9| |thyroid|0/2| |upper aerodigestive|0/22| |urinary tract|0/29| |uterus|0/5| == Essentiality in NALM6 == * **Essentiality Rank**: 8952 * **Expression level (log2 read counts)**: 1.31 {{:chemogenomics:nalm6 dist.png?nolink |}}